Aridis Pharmaceuticals, Inc.

92 articles with Aridis Pharmaceuticals, Inc.

• Aridis Pharmaceuticals Receives Multiple NIH Grants

  10/13/2015

• Aridis Pharmaceuticals Receives FDA Fast Track Designation For AR-301 For Acute Pneumonia Caused By Staphylococcus Aureus

  9/11/2015

• Aridis Pharmaceuticals Appoints Fred Kurland As Chief Financial Officer

  7/14/2015

• Aridis Pharmaceuticals Expands Phase 2a Trial Into The U.S. For Monoclonal Antibody AR-301 For The Treatment Of Acute Pneumonia

  7/8/2015

• Aridis Pharmaceuticals Receives FDA Fast Track Designation For Aerucin For Treating Hospital-Acquired And Ventilator-Associated Pneumonia

  6/30/2015

• Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, To Board Of Directors

  4/9/2015

• Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia

  3/26/2015

• Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., As Chief Medical Officer

  3/23/2015

• Aridis Pharmaceuticals Appoints Dr. Steven Opal To Scientific Advisory Board

  12/1/2014

• Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech

  5/17/2013

• EnWave Corporation and Aridis Pharmaceuticals Sign Collaboration Agreement-Relationship Expanded to Include Antibodies

  7/11/2007

• EnWave Corporation, Aridis Pharmaceuticals Sign Letter of Intent

  3/29/2007